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Microabstract  
We evaluated the relationship between systematic inflammatory markers (C-
reactive protein, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio) and 
survival in a cohort of 63 patients with metastatic renal cell carcinoma receiving 
2nd-lilne molecular-targeted therapy after 1st-line tyrosine kinase inhibitor failure. 
Each marker was associated with progression-free and overall survival. In 
particular, C-reactive protein was a strong independent predictive biomarker of 
prognosis.  
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Abstract  
Background: The role of systemic inflammatory markers, including C-reactive 
protein (CRP), the neutrophil/lymphocyte ratio (NLR), and the platelet/lymphocyte 
ratio (PLR), in predicting survival for patients with metastatic renal cell carcinoma 
(mRCC) receiving 2nd-line molecular-targeted therapy (mTT) after 1st-line tyrosine 
kinase inhibitor failure remains unclear. Thus, we investigated the relationship 
between systemic inflammation and survival in such patients. 
Patients and Methods: Sixty-three patients were evaluated. Progression-free 
survival (PFS) and overall survival (OS) after 2nd-line mTT initiation were 
evaluated based on inflammatory markers. In addition, the prognostic factors for 
survival were examined.  
Results: The receiver operating characteristic curves for CRP, NLR, and PLR had 
areas under the curve of 0.779, 0.619, and 0.655, respectively; no significant 
differences were noted. The cutoff values were 0.48, 2.53, and 183, respectively. 
Patients with higher CRP (n = 40), NLR (n = 32), and PLR (n = 22) had 
significantly lower PFS and OS compared to those with lower CRP, NLR, and 
PLR. Multivariate analyses showed that CRP was the sole independent predictor 
for PFS and OS.  
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Conclusion: Systemic inflammation is associated with survival after 2nd-line mTT. 
In particular, CRP was a strong independent predictive biomarker of prognosis.  
 
Keywords 
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biomarker; prediction 
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Introduction 
The current treatment strategy for metastatic renal cell carcinoma (mRCC) 
consists of molecular-targeted therapy (mTT) to improve and prolong patient 
survival 1. To further improve treatment strategy and, consequently, patient 
survival, identifying predictive factors or risk classifications are necessary. 
The functional relationship between systemic inflammation and cancer is well 
recognized 2, 3. The tumor microenvironment, which is orchestrated by 
inflammatory cells, is an indispensable factor in the neoplastic process, fostering 
cell proliferation, survival and migration 4. In renal cell carcinoma (RCC), an 
association between systemic inflammation and prognosis has been 
demonstrated. C-reactive protein (CRP) has been identified as an independent 
predictive biomarker for survival in patients with RCC with or without metastasis 
5-9. Moreover, the neutrophil/lymphocyte ratio (NLR) has been identified as an 
effective predictor in patients with mRCC receiving mTT 10, 11. These relationships 
have been attributed to the mechanism in which RCC cells produce inflammatory 
cytokines, such as interleukin-6, inducing CRP and neutrophils 12-15. Furthermore, 
the platelet/lymphocyte ratio (PLR) has been identified as a predictive biomarker 
in patients with cancers, including RCC 16-18. Several platelet-derived cytokines 
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related to tumor angiogenesis regulation, such as vascular endothelial growth 
factor, basic fibroblast growth factor, and platelet-derived growth factor, have 
been found to be elevated in patients with cancer 19, 20. 
In a recent retrospective large-scale study, neutrophil and platelet levels were 
found to be independent predictive factors of prognosis in patients with mRCC 
who received 2nd-line mTT after progression from 1st-line therapy 21. Therefore, 
we hypothesized that NLR and/or PLR would also be associated with patient 
survival after 2nd-line mTT. Indeed, to the best of our knowledge, the effect of NLR 
or PLR in predicting survival in a 2nd-line setting remains unclear, although this 
has been demonstrated in 1st-line therapy 10, 18. Moreover, the association among 
systematic inflammatory markers, including CRP, NLR, and PLR, in a 2nd-line 
setting is unknown.  
Thus, we investigated the correlation among systemic inflammatory markers, 
(CRP, NLR, and PLR), as well as influence of these biomarkers in the predicting 
of survival in patients with mRCC receiving 2nd-line mTT after 1st-line TKI failure. 
 
Patients and Methods 
Patient and study design 
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Of the 115 patients who received 2nd-line mTT at our department between 
January 2007 and August 2016, those who had received prior cytokine therapy 
(n = 23), received dialysis therapy (n = 6), shifted to 2nd-line mTT because of 
adverse events in 1st-line therapy (n = 11), received the mammalian target of 
rapamycin inhibitor (mTORi) as a 1st-line agent (n = 7), and had missing data (n 
= 22) were excluded. The remaining 63 patients were evaluated. Clinical and 
laboratory data were obtained from an electronic database and the patients’ 
medical records.  
The Internal Ethics Review Board of Tokyo Women’s Medical University 
approved this retrospective study (ID: 4109), which was performed in accordance 
with the principles outlined in the Declaration of Helsinki.  
 
Systemic inflammatory markers 
We evaluated three systemic inflammatory markers; CRP, NLR, and PLR, which 
were examined within 1 month prior to the initiation of 2nd-line mTT. All markers 
were obtained from the same blood sample, and all laboratory tests were 
performed at the same facility (i.e., Tokyo Women’s Medical University).   
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Endpoints   
The endpoints included progression-free survival (PFS) and overall survival 
(OS) after 2nd-line mTT. PFS was defined as the time from 2nd-line mTT initiation 
to the date of progression or death from any cause, while OS was defined as the 
time from 2nd-line mTT initiation to death from any cause. 
 
Statistical analysis  
PFS and OS were calculated using the Kaplan-Meier method, and statistical 
significance was determined using the log-rank test. The ability of the three 
systemic inflammatory markers to predict PFS was evaluated using the are under 
curve (AUC) in a receiver operating characteristics (ROC) curve analysis. The 
cutoff values for the three markers were defined using the maximum Youden 
index 22. Moreover, to examine the relationships between CRP and NLR, CRP 
and PLR, and NLR and PLR, the three markers were plotted against each other 
in scatter plots, and the Pearson’s correlation coefficient was calculated. PFS and 
OS were compared based on cutoff values. Univariate and multivariate analyses 
for PFS and OS were performed using the Cox proportional hazards model. To 
manage larger statistical effects for the categorical classification based on 
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dichotomous values in CRP, NLR and PLR, we performed multivariate analyses 
modeling these markers both as a categorical classification (Model 1) and as a 
continuous variable (Model 2). Survival risk was expressed as hazard ratios 
(HRs) and 95% confidence intervals (CIs). All statistical analyses were performed 
using JMP software (version 11; SAS Institute Inc., Cary, NC, USA), and a P-
value <0.05 was considered statistically significant. 
 
Results  
Patient background  
Table 1 shows the patients’ characteristics. Thirty-six patients were ≥65 years 
old (57.1%), and 44 patients were male (69.8%). Clear-cell carcinoma (CCC) was 
observed in 48 patients (76.2%), and non-CCC, including papillary renal cell 
carcinoma, CCC with spindle, Bellini duct carcinoma, medullary carcinoma, 
mucinous tubular and spindle cell carcinoma, and unknown, were observed in 5 
(7.94%), 4 (6.35%), 1 (1.59%), 1 (1.59%), 1 (1.59%), and 3 (4.76%) patients, 
respectively. Prior nephrectomy was performed in 58 patients (92.1%), including 
partial and radical nephrectomy in 1 (1.59%) and 57 (90.5%) patients, 
respectively. Metastasis was found in the lung, bone, liver, and lymph node in 52 
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(82.5%), 13 (20.6%), 11 (17.5%), and 19 (30.2%) patients, respectively; 42 
patients (66.7%) had multiple metastasis. Sorafenib, sunitinib, and pazopanib 
were administered as 1st-line TKI in 22 (34.9%), 38 (60.3%), and 3 (4.76%) 
patients, respectively. TKI and mTORi were administered as a 2nd-line mTT agent 
in 52 (82.5%) and 11 (17.5%) patients, respectively. TKI included sorafenib (n = 
2, 3.18%), sunitinib (n = 15, 23.8%), axitinib (n = 32, 50.8%), and pazopanib (n = 
3, 4.76%); mTORi included temsirolimus (n = 3, 4.76%) and everolimus (n = 8, 
12.7%). Based on the 1st-line Memorial Sloan Kettering Cancer Center (MSKCC) risk 
classification, 9 (14.3%), 47 (74.6%), and 7 (11.1%) patients were classified as 
favorable, intermediate, and poor, respectively. Thirty-six patients (57.1%) had ≥8 
months of 1st-line PFS. Based on the 2nd-line MSKCC risk classification, identified 
according to Motzer’s risk classification 23, 5 (7.94%), 42 (66.7%), and 16 (25.4%) 
patients were classified as favorable, intermediate, and poor, respectively. Means 
± standard deviation (SD) for the absolute value of CRP, neutrophil count, 
lymphocyte count, platelet count, NLR, and PLR at the time of 2nd-line initiation 
were 2.16 ± 3.27 mg/dL, 3300 ± 1600/mm3, 1300 ± 510/mm3, 190,000 ± 
84,000/mm3, 3.09 ± 2.71, and 166.5 ± 101.7, respectively. According to the 
Common Terminology Criteria for Adverse Events ver. 4.0, due to 
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myelosuppression from 1st-line therapy evaluated at the time of 2nd-line initiation, 
grade 2 neutropenia, lymphocytopenia, and thrombocytopenia were observed in 
8 (12.7%), 2 (3.18%), and 3 patients (4.76%), and grade 3 were observed in 1 
(1.59%), 3 (4.76%), and 1 patient (1.59%), respectively. Mean ± SD at follow-up 
was 16.3 ± 12.6 months.  
 
Association between systemic inflammatory markers and survival  
Using the maximum Youden index, 0.48, 2.53, and 183 were selected as the 
optimal threshold value for CRP, NLR, and PLR, respectively. Based on these 
cutoffs, ROC analyses were conducted to evaluate the association between the 
three markers and PFS. The AUC for CRP, NLR, and PLR was 0.779 (95% CI 
0.604-0.891), 0.619 (0.463-0.754), and 0.655 (0.513-0.775), respectively. No 
significant differences among the AUCs for the markers (P = 0.251) were 
observed (Figure 1). Patients were classified into high systemic inflammatory 
marker and low marker groups (i.e., high CRP, NLR, and PLR groups). Patients 
in the high CRP group (n = 40) had significantly lower PFS and OS compared to 
those in the low CRP group (median PFS: 4.74 vs. 19.9 months; OS: 9.6 vs. 38.7 
months, P’s < 0.0001; Figures 2A and 2B). Similarly, patients in the high NLR 
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group (n = 31) had significantly lower PFS and OS compared to those in the low 
NLR group (median PFS: 5.07 vs. 8.19 months, P = 0.0059; OS: 10.4 vs. 28.8 
months, P = 0.0006; Figures 2C and 2D). In addition, patients in the high PLR 
group (n = 22) had significantly lower PFS and OS compared to those in the low 
PLR group (median PFS: 3.69 vs. 8.82 months, P < 0.0001; OS: 9.11 vs. 28.0 
months, P < 0.0001; Figures 2E and 2F).  
 
Relationships among systemic inflammatory markers  
A strong correlation was found between NLR and PLR (R2 = 0.675, P < 0.0001). 
The relationship between CRP and NLR (R2 = 0.119, P = 0.0056) and between 
CRP and PLR (R2 = 0.132, P = 0.0034) were weak, although statistical 
significance was found (Figures 3A-C).   
  
Independent predictors for survival 
Univariate analyses for PFS and OS showed that pathology, 1st-line PFS, the 
2nd-line MSKCC risk classification, CRP, NLR and PLR were significant predictors 
(all P < 0.05), whereas other factors, including age, sex, 2nd-line agent, or the 1st-
line MSKCC risk classification were insignificant predictors (all P > 0.05). 
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Multivariate analysis for PFS showed that CRP was an independent predictor 
both as a categorical classification in Model 1 (HR 3.72, p = 0.0007) and as a 
continuous variable in Model 2 (HR 1.27, p < 0.0001), while PLR was an 
independent predictor only as a categorical classification in Model 1 (HR 2.81, p 
= 0.0233) (Table 2). Multivariate analysis for OS showed that CRP was an 
independent predictive biomarker both as a categorical classification (HR 2.67, p 
= 0.0268) and as a continuous variable in Models 1 and 2 (HR 1.31, p < 0.0001) 
(Table 3). 
  
Discussion 
A close relationship between systemic inflammation and prognosis in RCC has 
been recognized. Chronic systemic inflammation caused by CRP or neutrophils 
produced by cancer cells can affect the host’s nutritional condition, resulting in a 
poor prognosis, by directly accelerating tumor growth/dissemination or impairing 
treatment tolerability 24, 25. Moreover, lymphocytes play a role in the host’s 
immunity against cancers and are thought to possess an antitumor effect by 
inducing cell apoptosis, suppressing tumor growth and migration, and mediating 
cytotoxicity 3. Although CRP, NLR, and PLR have been identified as effective 
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biomarkers, the correlation among them in patients with mRCC remains unclear, 
and the role of these markers as predictors for survival with 2nd-line mTT is also 
controversial. To the best of our knowledge, this is the first study demonstrating 
that pre-treatment values of NLR, and PLR are closely related, and that patients 
with high CRP, NLR, and PLR have lower PFS and OS with 2nd-line mTT after 1st-
line TKI failure in mRCC. Finally, CRP appears to be a strong, independent 
predictive biomarker for PFS and OS.  
 CRP has been identified as an independent biomarker for survival in patients 
with RCC with or without metastasis 5-9. In mTT, the predictive value of CRP has 
been demonstrated 9, 26. However, clinical information on CRP as a predictive 
biomarker in 2nd-line mTT after 1st-line TKI failure is limited 27. Similarly, studies 
evaluating the prognostic value of NLR and PLR with 2nd-line mTT are few. Ko et 
al. previously indicated that neutrophilia and thrombocytosis were independent 
factors for OS following the initiation of 2nd-line therapy after progression from 1st-
line therapy for mRCC 21. However, in the present study, after adjustment for CRP, 
PLR’s predictive value was only observed for PFS as a categorical classification, 
while NLR was not significantly associated with PFS or OS; these findings 
seemed to be partially inconsistent with the previous report by Ko et al. 21. We 
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speculate that two potential reasons for this discrepancy exist. First, different 
models in the multivariate analyses were used 21 (i.e., a factor of ‘CRP’ was not 
incorporated in the previous study). Therefore, a different analysis model might 
have resulted in a different statistical finding. Second, a possible 
myelosuppression due to 1st-line therapy may have caused neutropenia, 
lymphocytopenia or platelet depletion. A previous study reported that 15-20% of 
patients experienced myelosuppression after TKI treatment including sunitinib 28. 
Although sorafenib is considered to be safer than sunitinib, 10% of patients 
experience cytopenia with 1st-line sorafenib therapy in the Japanese population 
29. In the present cohort, sunitinib and sorafenib were used in the majority of 
patients as a 1st-line agent; therefore, the myelosuppressive effect possibly 
existed. Indeed, a few patients displayed myelosuppression at the time of 2nd-line 
initiation, as shown in Table 1.   
 This study has several limitations. First, a retrospective single-center design with 
a relatively small cohort was used, possibly resulting in bias. Second, the enrolled 
patients received different targeted agents. Although a univariate analysis 
showed no statistical difference in survival based on the type of agent, a possible 
bias may still exist. Third, the rate of adverse events and relative dose intensity 
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were not evaluated.  
 
Conclusion  
Systemic inflammatory markers (specifically, CRP, NLR, and PLR) have 
prognostic value for PFS and OS in patients with mRCC receiving 2nd-line mTT 
after 1st-line TKI failure. Furthermore, CRP was demonstrated to be a strong 
independent predictive biomarker. Patients with systemic inflammation have a 
poor prognosis despite 2nd-line therapy initiation. Therefore, careful follow-up 
must be performed for such high-risk patients. In addition, these markers may be 
used to determine the best use of 2nd-line agents. 
 
Clinical practice points 
 We demonstrated the impact of systematic inflammatory markers, including 
CRP, NLR, and PLR on predicting PFS and OS in a cohort of 63 patients with 
mRCC who received 2nd-line mTT after 1st-line TKI failure. 
 Patients with higher CRP, NLR, and PLR had significantly lower PFS and OS 
after 2nd-line mTT, compared to those with lower CRP, NLR and PLR (p’s < 
0.05). 
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 Pre-treatment NLR and PLR were closely related (R2 = 0.675), whereas CRP 
was not strongly associated with NLR (R2 = 0.119) or PLR (R2 = 0.132). 
 Pre-treatment CRP was a strong independent predictive biomarker of PFS 
and OS after 2nd-line mTT for mRCC as a categorical classification (PFS: HR 
3.72 p = 0.0007, OS: HR 2.67 p = 0.0288) and as a continuous variable (PFS: 
HR 1.27 p < 0.0001, OS: HR 1.31 p < 0.0001), after adjusting for other factors 
including pathology, 1st-line PFS, 2nd-line MSKCC, NLR, and PLR.  
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Figure legends 
Figure 1: Comparisons among systemic inflammatory markers in the area under 
the ROC curves for PFS.  
No significant differences in AUCs among CRP, NLR, and PLR (P = 0.251) were 
found. 
ROC, receiver operating characteristics; PFS, progression-free survival; AUC, 
area under the curve; CRP, C-reactive protein; NLR, neutrophil/lymphocyte 
ratio; PLR, platelet/lymphocyte ratio 
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Figure 2: (A-B) The patients were classified into high (n = 40) and low (n = 23) 
CRP groups, according to the cutoff of 0.48. PFS and OS were significantly 
lower in patients with high CRP (both, P < 0.0001). (C-D) The patients were 
classified into high (n = 31) and low (n= 32) NLR groups, according to the cutoff 
of 1.15. PFS and OS were significantly lower in patients with high NLR (PFS, P 
= 0.0059; OS, P = 0.0006). (E-F) The patients were classified into high (n = 22) 
and low (n = 41) PLR groups, according to the cutoff of 183. PFS and OS were 
significantly lower in patients with high PLR (both P < 0.0001). 
CRP, C-reactive protein; PFS, progression-free survival; OS, overall survival; 
NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio 
 
Figure 3: Correlations between systemic inflammatory markers.  
(A) CRP and NLR. (B) CRP and PLR. (C) NLR and PLR. A strong correlation 
was observed between NLR and PLR (R2 = 0.675, P < 0.0001). 
Table 1: Patient characteristics  
Variable All (n = 63) 
Age at the time of 2nd-line mTT initiation, year 
 ≥ 65 (ref. < 65) 
 
36 (57.1%) 
Sex  
 Male (ref. female) 
 
44 (69.8%) 
Pathology 
 CCC  
 Non-CCC 
  Papillary renal cell carcinoma type2 
  CCC with spindle  
  Bellini duct carcinoma 
  Medullary carcinoma 
  Mucinous tubular and spindle cell carcinoma 
  Unknown  
 
48 (76.2%) 
15 (23.8%) 
5 (7.94%) 
4 (6.35%) 
1 (1.59%) 
1 (1.59%) 
1 (1.59%) 
3 (4.76%) 
Prior nephrectomy  
 With (ref. without) 
  Partial/radical 
 
58 (92.1%) 
1 (1.59%)/57 (90.5%) 
Metastatic sites at the time of 2nd-line mTT initiation  
 Lung 
 Bone 
 Liver 
 Lympho node 
 Others   
Number of metastatic lesion  
 Multiple (ref. solitary) 
 
52 (82.5%) 
13 (20.6%) 
11 (17.5%) 
19 (30.2%) 
3 (4.76%) 
 
42 (66.7%) 
1st-line TKI 
 Sorafenib 
 Sunitinib 
 Pazopanib   
 
22 (34.9%) 
38 (60.3%) 
3 (4.76%) 
2nd-line mTT  
 TKI  
  Sorafenib 
  Sunitinib 
  Axitinib 
  Pazopanib 
 
52 (82.5%) 
2 (3.18%) 
15 (23.8%) 
32 (50.8%) 
3 (4.76%) 
 mTORi 
  Temsirolimus 
  Everolimus  
11 (17.5%) 
3 (4.76%) 
8 (12.7%) 
1st-line MSKCC risk classification  
 Favorable/intermediate/poor 
 
9 (14.3%)/47 (74.6%)/7 (11.1%) 
1st-line PFS, months  
 ≥ 8 (ref. < 8) 
 
36 (57.1%) 
2nd-line MSKCC risk classification  
 Favorable/intermediate/poor  
 
5 (7.94%)/ 42 (66.7%)/ 16 (25.4%) 
aCRP at the time of 2nd-line initiation, mg/dL 2.16 ± 3.27 
a Neutrophil count, /mm3   3300 ± 1600 
a Lymphocyte count, /mm3 1300 ± 510 
a Platelet count, /mm3 190,000 ± 84,000 
aNLR 3.09 ± 2.71 
aPLR 166.5 ± 101.7 
Neutropenia at the time of 2nd-line initiation 
Grade 2 
Grade 3  
 
8 (12.7%) 
1 (1.59%) 
Lymphocytopenia at the time of 2nd-line initiation  
Grade 2 
 Grade 3 
 
2 (3.18%) 
3 (4.76%) 
Thrombocytopenia at the time of 2nd-line initiation 
 Grade 2 
 Grade 3 
 
3 (4.76%) 
1 (1.59%) 
a Follow-up, month 16.3 ± 12.6 
a Mean ± standard deviation (SD) 
CCC, clear-cell carcinoma; mTT; molecular-targeted therapy; TKI, tyrosine 
kinase inhibitor; mTORi, mammalian target of rapamycin inhibitor; MSKCC, 
Memorial Sloan Kettering Cancer Center; PFS, progression-free survival; CRP, 
C-reactive protein; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte 
ratio; ref., reference   
 
 
 
 
 
Table 2: Univariate and multivariate analyses for PFS  
 
Univariate 
HR (95% CI) 
p *Model 1 
Multivariate  
HR (95% CI) 
p **Model 2 
Multivariate  
HR (95% CI) 
p 
Age 
 ≥ 65 (ref. < 65) 
 
0.67 (0.38 – 1.18) 
0.165 
    
Sex 
 Male (ref. female) 
 
0.75 (0.42 – 1.39) 
0.349 
    
Pathology  
 Non-CCC (ref. CCC) 
 
2.82 (1.44 – 5.24) 
0.0033  
1.19 (0.52 – 2.60) 
0.678  
2.03 (0.93 – 4.20) 
0.0725 
1st-line agent 
 Sorafenib (ref. sunitinib/pazopanib) 
 
0.93 (0.49 – 1.68) 
0.815 
    
2nd-line agent 
 TKI (ref. mTORi) 
 
0.67 (0.35 – 1.37) 
0.256 
    
1st-line MSKCC 
 Poor (ref. favorable/intermediate) 
 
1.01 (0.35 – 2.32) 
0.987 
    
1st-line PFS 
 < 8 month (≥ 8 months) 
 
2.76 (1.53 – 4.98) 
0.0009  
1.94 (0.99 – 3.76) 
0.0541  
1.95 (0.95 – 3.90) 
0.0700 
2nd-line MSKCC 
 Poor (ref. favorable/intermediate) 
 
2.82 (1.45 – 5.26) 
0.0028  
1.72 (0.77 – 3.66) 
0.178  
1.72 (0.77 – 3.59) 
0.178 
CRP 
 ≥ 0.48 (ref. < 0.48) 
 
5.42 (2.77 – 11.5) 
<0.0001  
3.72 (1.72 – 8.45) 
0.0007 - - 
NLR 
 ≥ 2.53 (ref. < 2.53) 
 
2.20 (1.24 – 3.98) 
0.0069  
0.79 (0.34 – 1.77) 
0.575 - - 
PLR 
 ≥ 183 (ref. < 183) 
 
3.75 (2.06 – 6.79) 
<0.0001  
2.81 (1.15 – 7.22) 
0.0233 - - 
CRP (continuous variable) 1.32 (1.20 – 1.46) <0.0001 - - 1.27 (1.13 – 1.42) <0.0001 
NLR (continuous variable) 1.14 (1.03 – 1.23) 0.0154 - - 1.10 (0.92 – 1.29) 0.264 
PLR (continuous variable) 1.00 (1.00 – 1.01) 0.0057 - - 1.00 (0.99 – 1.00) 0.929 
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, 
confident interval; CCC, clear-cell carcinoma; TKI, tyrosine kinase inhibitor; 
mTORi, mammalian target of rapamycin inhibitor; MSKCC, Memorial Sloan 
Kettering Cancer Center; CRP, C-reactive protein; NLR, neutrophil/lymphocyte 
ratio; PLR, platelet/lymphocyte ratio; ref., reference  
*Model 1: Modeling with systematic inflammatory markers as a categorical classification  
**Model 2: Modeling with systematic inflammatory markers as a continuous variable  
Table 3: Univariate and multivariate analyses for OS 
 
Univariate 
HR (95% CI) 
p *Model 1 
Multivariate  
HR (95% CI) 
p **Model 2 
Multivariate 
HR (95% CI) 
p 
Age 
 ≥ 65 (ref. < 65) 
 
0.70 (0.38 – 1.31) 
0.263 
    
Sex 
 Male (ref. female) 
 
0.78 (0.42 – 1.51) 
0.451 
    
Pathology  
 Non-CCC (ref. CCC) 
 
2.45 (1.18 – 4.79) 
0.0174  
1.24 (0.56 – 2.67) 
0.589  
2.30 (1.07 – 4.67) 
0.0330 
1st-line agent 
 Sorafenib (ref. sunitinib/pazopanib) 
 
1.09 (0.56 – 2.04) 
0.792 
    
2nd-line agent 
 TKI (ref. mTORi) 
 
1.26 (0.61 – 2.87) 
0.548 
    
1st-line MSKCC 
 Poor (ref. favorable/intermediate) 
 
0.90 (0.22 – 2.54) 
0.863 
    
1st-line PFS 
 < 8 month (≥ 8 months) 
 
2.41 (1.30 – 4.49) 
0.0057  
2.13 (1.11 – 4.10) 
0.0239  
1.68 (0.82 – 3.45) 
0.157 
2nd-line MSKCC 
 Poor (ref. favorable/intermediate) 
 
2.65 (1.31 – 5.10) 
0.0076  
1.20 (0.55 – 2.47) 
0.639  
2.46 (1.06 – 5.41) 
0.0369 
CRP 
 ≥ 0.48 (< 0.48) 
 
4.95 (2.37 – 11.6) 
<0.0001  
2.67 (1.12 – 6.91) 
0.0268 - - 
NLR 
 ≥ 2.53 (< 2.53) 
 
3.10 (1.60 – 6.30) 
0.0007  
1.09 (0.39 – 2.86) 
0.858 - - 
PLR 
 ≥ 183 (< 183) 
 
4.31 (2.25 – 8.39) 
<0.0001  
2.50 (0.91 – 7.58) 
0.0750 - - 
CRP (continuous variable) 1.30 (1.18 – 1.43) <0.0001 - - 1.31 (1.16 – 1.49) <0.0001 
NLR (continuous variable) 1.12 (1.03 – 1.21) 0.0140 - - 1.09 (0.91 – 1.30 0.343 
PLR (continuous variable) 1.00 (1.00 – 1.01) 0.0081 - - 1.00 (0.99 – 1.00) 0.629 
*Model 1: Modeling with systematic inflammatory markers as a categorical classification  
**Model 2: Modeling with systematic inflammatory markers as a continuous variable  
 



